1. Calcium Modulation and Clinical Effect

   • H. Timmerman

   Introductory Lecture 22 November 2012 Pages: 1 - 4

2. The Contribution of Haemorheology to the Understanding of Microcirculatory Disorders

   • P. Teitel

   Introductory Lecture 22 November 2012 Pages: 5 - 11

3. Microcirculation and Neurotransmitter Metabolism in the Pathophysiology of Brain Ischaemia

   • M. S. Magnoni
   • S. Govoni
   • M. Trabucchi

   Introductory Lecture 22 November 2012 Pages: 12 - 18

4. Primary and Secondary Blood Hyperviscosity Syndromes, and Syndromes Associated with Blood Hyperviscosity

   • Sandro Forconi
   • D. Pieragalli
   • R. Cappelli

   Introductory Lecture 22 November 2012 Pages: 19 - 26

5. Discussion Introductory Lectures

   • H. Timmerman

   Introductory Lecture 22 November 2012 Pages: 27 - 29

6. Influence of Cyclandelate on In Vitro Red Blood Cell Deformability

   • D. W. R. Hall
   • W. E. van den Hoven

   Section 1: Pharmacological Studies: Modes and Mechanisms of Action 22 November 2012 Pages: 30 - 40

7. Inhibition of Human Platelet Functions by Cyclandelate

   • W. E. van den Hoven
   • D. W. R. Hall

   Section 1: Pharmacological Studies: Modes and Mechanisms of Action 22 November 2012 Pages: 41 - 52

8. The Influence of Cyclandelate on Ca⁺⁺ Translocation in Human Platelets

   • J. W. N. Akkerman
   • W. E. van den Hoven

   Section 1: Pharmacological Studies: Modes and Mechanisms of Action 22 November 2012 Pages: 53 - 59

9. Effect of Cyclandelate on Prostacyclin Release and Cytosolic Free Calcium Concentrations in Human Endothelial Cells

   • V. W. M. van Hinsbergh

   Section 1: Pharmacological Studies: Modes and Mechanisms of Action 22 November 2012 Pages: 60 - 66

10. Cyclandelate as a Calcium Modulating Agent in Rat Cerebral Cortex

    • A. Bast
    • R. Leurs
    • H. Timmerman

    Section 1: Pharmacological Studies: Modes and Mechanisms of Action 22 November 2012 Pages: 67 - 74

11. Cyclandelate

    • Bruce Middleton
    • Francesca Cacciaguerra
    • David White

    Section 1: Pharmacological Studies: Modes and Mechanisms of Action 22 November 2012 Pages: 75 - 79

12. Discussion Section 1

    • H. Timmerman

    Section 1: Pharmacological Studies: Modes and Mechanisms of Action 22 November 2012 Pages: 80 - 81

13. Opening Remarks

    • M. S. J. Pathy

    Section 2: Clinical Studies 22 November 2012 Pages: 82 - 83

14. The Memory Clinic

    • Antony J. Bayer
    • M. S. John Pathy
    • Charles Twining

    Section 2: Clinical Studies 22 November 2012 Pages: 84 - 89

15. Cyclandelate versus Flunarizine

    • M. G. Albizzati
    • S. Bassi
    • L. Frattola

    Section 2: Clinical Studies 22 November 2012 Pages: 90 - 96

16. Specific Effects of Cyclandelate on Memory

    • Jambur Ananth

    Section 2: Clinical Studies 22 November 2012 Pages: 97 - 102

17. Comparative Efficacy of Cyclandelate versus Flunarizine in the Prophylactic Treatment of Migraine

    • G. Nappi
    • G. Sandrini
    • G. Micieli

    Section 2: Clinical Studies 22 November 2012 Pages: 103 - 109

18. Cyclandelate in the Treatement of Multi-Infarct Dementia

    • C. B. Blakemore

    Section 2: Clinical Studies 22 November 2012 Pages: 110 - 113

19. Cyclandelate in the Treatment of Vertigo of Circulatory Origin

    • F. de Halleux

    Section 2: Clinical Studies 22 November 2012 Pages: 114 - 119

20. Perceived Efficacy of Cyclandelate in the Treatment of Cochleovestibular and Retinal Disturbances Related to Cerebrovascular Insufficiency

    • Y. Memin

    Section 2: Clinical Studies 22 November 2012 Pages: 120 - 124

21. Clinical Experience with Cyclandelate in Insulin-Dependent Diabetic Patients with Neuropathy

    • I. H. De Leeuw
    • P. Van Rooy
    • M. Driessens

    Section 2: Clinical Studies 22 November 2012 Pages: 125 - 130

22. The Effect of Cyclandelate on Cholesterol Metabolism in Patients with Familial Hypercholesterolaemia

    • J. A. Gevers Leuven
    • H. v. d. Voort
    • L. Havekes

    Section 2: Clinical Studies 22 November 2012 Pages: 131 - 135

23. Panel Discussion

    • M. Pathy
    • H. Timmerman

    Section 2: Clinical Studies 22 November 2012 Pages: 136 - 139

24. Closing Remarks

    • M. O’Brien

    Section 2: Clinical Studies 22 November 2012 Pages: 140 - 141